Two part (double-blind inclisiran versus placebo [Year 1]followed by open-label inclisiran [Year 2]) randomizedmulticenter study to evaluate safety, tolerability, andefficacy of inclisiran in adolescents (12 to less than 18years) with heterozygous familial hypercholesterolemiaand elevated LDL-cholesterol (ORION-16)
Gökçay G. F. (Executive), Karaca M., Balcı M. C.
Other International Funding Programs, 2020 - 2022
-
Project Type:
Other International Funding Programs
-
Begin Date:
September 2020
-
End Date:
December 2022